Sepsis Research Analysis
Q2 2026 sepsis research converged on host-directed control of inflammation and injury, rapid resistance diagnostics, and organ-specific metabolic therapy. April inaugurated an inflammasome-focused wave with an LRR-binding NLRP3 inhibitor (LOC14) and dual NLRP3–NCF1 redox targeting, which set the stage for May’s repurposed NLRP3 inhibitor ciclopirox with immediate translational potential. Cross-cutting immunometabolism advanced through discovery that itaconate alkylates AIM2 to trigger macrophage
Summary
Q2 2026 sepsis research converged on host-directed control of inflammation and injury, rapid resistance diagnostics, and organ-specific metabolic therapy. April inaugurated an inflammasome-focused wave with an LRR-binding NLRP3 inhibitor (LOC14) and dual NLRP3–NCF1 redox targeting, which set the stage for May’s repurposed NLRP3 inhibitor ciclopirox with immediate translational potential. Cross-cutting immunometabolism advanced through discovery that itaconate alkylates AIM2 to trigger macrophage PANoptosis, while kidney-protective metabolic regulation via the GATM–PDK4 axis clarified a tractable sepsis-AKI target. A circulating hemolytic mediator (PLA2G5) linked mechanism, prognostic biomarker, and druggability in one arc. Finally, MALCA delivered same-day carbapenemase typing directly from routine antibiograms, complementing pragmatic clinical evidence showing no renal-outcome advantage of balanced crystalloids over saline in pediatric septic shock.
Selected Articles
1. RPSA-OLFM4 axis governs neutrophil migration against bacterial infection and sepsis.
A myeloid RPSA–OLFM4 checkpoint sustains RhoA/ROCK1/pMLC2 signaling and MYH9 uropod localization to enable neutrophil migration; perturbation impairs trafficking and worsens outcomes, while therapeutic modulation restores migration and survival, including validation in septic patient neutrophils.
Impact: Identifies a tractable, human-validated migratory checkpoint that directly links cytoskeletal polarity to host defense in sepsis, offering a new lever for host-directed therapy.
Clinical Implications: Supports biomarker development (RPSA/OLFM4 phenotyping) and early-phase trials to restore neutrophil trafficking and bacterial clearance in selected patients.
Key Findings
- Myeloid-specific Rpsa deletion reduces neutrophil infiltration and worsens infection outcomes.
- RPSA deficiency induces OLFM4, disrupts RhoA/ROCK1/pMLC2 signaling, and mislocalizes MYH9 from uropods.
- Therapeutic targeting restores migration and survival; septic patient neutrophils show RPSAlow/OLFM4high.
2. Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.
PLA2G5 is induced in intestinal cells during sepsis, circulates to drive intravascular hemolysis via erythrocyte membrane lipolysis; genetic deletion or neutralizing antibody protects mice, and plasma levels in patients predict severity and mortality.
Impact: Uncovers a circulating mediator with prognostic value and therapeutic tractability, linking mechanistic pathophysiology to human biomarker and in vivo intervention.
Clinical Implications: Enables development of PLA2G5 assays for risk stratification and motivates antibody or small-molecule blockade to mitigate hemolysis in sepsis.
Key Findings
- PLA2G5 induction in colon cells and appearance as a circulating factor during sepsis.
- Neutralization or knockout protects mice and improves iron homeostasis.
- Plasma PLA2G5 is elevated in human sepsis and predicts severity/mortality.
3. Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation.
High-throughput screening identified LOC14, an isothiazolinone that binds the NLRP3 LRR domain, inhibiting both MCC950-responsive and -resistant hyperactive variants and showing in vivo efficacy across inflammatory models including sepsis.
Impact: Introduces a mechanistically distinct NLRP3 inhibitor class that addresses MCC950 resistance, expanding therapeutic options for inflammasome-driven disease.
Clinical Implications: Enables development paths for patients with resistant variants or hyperinflammatory phenotypes; next steps include PK/tox profiling and translational biomarkers.
Key Findings
- LOC14 binds the NLRP3 LRR domain to selectively inhibit activation.
- Inhibits both MCC950-responsive and -nonresponsive hyperactive NLRP3 variants.
- Demonstrates in vivo efficacy across sepsis and other inflammatory models.
4. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.
The FDA-approved antifungal ciclopirox binds the NLRP3 NACHT domain, reducing ATPase activity and oligomerization; it improves outcomes in murine sepsis models and shows ex vivo activity in human cells, providing a repurposing path to NLRP3 inhibition.
Impact: Delivers an immediately testable repurposing strategy against a central inflammatory driver, accelerating translation from target to therapy.
Clinical Implications: Prioritize PK/PD and dose-ranging studies for systemic use in sepsis; if translatable, NLRP3 inhibition may blunt maladaptive inflammation in biomarker-selected patients.
Key Findings
- Selective NLRP3 inhibition without affecting other inflammasomes.
- Binds NACHT (e.g., Y381), reducing ATPase activity and oligomerization.
- Therapeutic dosing improved outcomes in murine sepsis; ex vivo human activity observed.
5. Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).
MALCA, a random-forest pipeline trained and externally validated on large antibiogram datasets, achieves ≥96% sensitivity/specificity for carbapenemase detection and ≥97%/≥98% for major types, enabling same-day, reagent-free typing from routine labs.
Impact: Transforms routine antibiogram outputs into rapid mechanism typing, reducing time to appropriate therapy and strengthening stewardship for resistant sepsis.
Clinical Implications: Integration into microbiology workflows can guide early selection of targeted agents (e.g., KPC/OXA-48-like vs NDM regimens) pending implementation studies.
Key Findings
- Trained on 11,992 and externally validated on 8,514 isolates.
- ≥96% sensitivity/specificity for carbapenemase detection; ≥97%/≥98% for OXA-48-like, NDM, and KPC typing.
- Outperformed established European/French screening algorithms using only routine data.
6. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
A large pragmatic randomized trial (~8,482 analyzed) across 47 emergency departments found no reduction in MAKE30 with balanced crystalloids versus 0.9% saline in pediatric septic shock, despite reduced electrolyte derangements.
Impact: Provides practice-defining evidence for a ubiquitous resuscitation choice, clarifying clinical equipoise without invoking guideline-centric metrics.
Clinical Implications: Either fluid is reasonable; individualize based on electrolytes and availability while prioritizing timely antibiotics and hemodynamic support.
Key Findings
- No significant difference in MAKE30 between balanced fluids and saline.
- Balanced fluids reduced hyperchloremia and hypernatremia without improving patient-centered outcomes.
- Pragmatic multinational design (ITT) supports external validity.
7. Dual targeting of NCF1 and NLRP3 by roburic acid orchestrates redox homeostasis and inhibits macrophage death in septic lung injury.
Roburic acid nanoparticles improved survival and reduced lung injury in CLP sepsis; chemical proteomics and CETSA identified NLRP3 (NACHT) and NCF1 as direct targets, coordinating inflammasome suppression with NOX2-derived ROS control to block pyroptosis and ferroptosis.
Impact: Links inflammasome biology to redox control with dual targeting and in vivo survival benefit, offering an integrative host-directed therapy for septic lung injury.
Clinical Implications: Suggests dual-mechanism agents may outperform single-target approaches in septic lung injury; needs safety, PK, and large-animal validation.
Key Findings
- Nanoparticle-delivered roburic acid improved survival and attenuated lung injury in CLP models.
- Direct intracellular targets identified as NLRP3 (NACHT) and NCF1.
- Dual inhibition suppressed inflammasome assembly, NOX2 complex formation, pyroptosis, and ferroptosis.
8. The alkylation of AIM2 by itaconate mediates macrophage PANoptosis during sepsis.
Pathologic itaconate covalently alkylates AIM2 at C113, stabilizing and activating it to drive ASC oligomerization and PANoptosis; mutational and in vivo data confirm the axis exacerbates systemic sepsis.
Impact: Links an immunometabolite to AIM2-driven PANoptosis, opening a novel druggable node for hyperinflammatory sepsis.
Clinical Implications: Suggests targeting AIM2 modification or downstream PANoptosis to preserve macrophages and limit hyperinflammation; requires human validation.
Key Findings
- Itaconate alkylates AIM2 at C113, stabilizing and activating AIM2.
- Activated AIM2 triggers ASC oligomerization and PANoptosome assembly leading to PANoptosis.
- In vivo models show the itaconate–AIM2 axis worsens systemic sepsis.
9. GATM alleviates sepsis-induced acute kidney injury via PDK4-mediated glycolytic reprogramming in renal tubular epithelial cells.
Cross-dataset analyses and preclinical validation identify GATM as a protective regulator in sepsis-AKI; GATM overexpression suppresses PDK4-driven glycolysis, lowers lactate, increases ATP, and mitigates tubular/mitochondrial injury, with PDK4 overexpression reversing protection.
Impact: Defines a tractable metabolic checkpoint (GATM–PDK4) for organ protection with in vivo rescue, offering a concrete target for sepsis-AKI.
Clinical Implications: Supports targeting PDK4 or augmenting GATM to restore mitochondrial energetics in sepsis-AKI; requires biomarkers and safety evaluation for translation.
Key Findings
- GATM is downregulated in proximal tubules during sepsis-AKI across datasets.
- AAV-mediated GATM overexpression improves renal function and reduces mitochondrial injury.
- GATM downregulates PDK4 and glycolytic markers; PDK4 overexpression abolishes protection.
10. Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.
A conserved NFATc1-bound enhancer (CNS-9 in mouse; CNS-12 in human) loops to the IL-10 promoter to drive B cell IL-10; enhancer deletion or B cell–specific NFATc1 loss reduces IL-10 and survival in endotoxemia.
Impact: Defines enhancer-level immunoregulation of IL-10 with survival impact, opening precise strategies to augment regulatory B cell function in sepsis.
Clinical Implications: Rationalizes pharmacologic/epigenetic approaches to enhance B cell IL-10 and suggests biomarkers of regulatory B cell function.
Key Findings
- CNS-9/CNS-12 acts as an NFATc1-bound enhancer looping to the IL-10 promoter.
- B1a cells are predominant IL-10 producers under this enhancer program.
- Enhancer or B cell–specific NFATc1 loss reduces IL-10 and survival in endotoxemia.